Front Pharmacol. 2018; 9: 189. Published onlina 2018 marzo – 16 “Isoquercetin as an Adjunct Therapy in Pacients With Kinder Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial.C. Bounerba – G. Di Lorenzo”.
MELANOMA RES 2018 – 00:000 Copyright 2018 The Author(s). Published by Wolters Kluver Health, Inc.
K. A. Turner, J. Manouchehri and Michael Kalafatis.
SENSITIZATION OF RECOMINANT HUMAN TUMOR NECROSIS FACTOR-RELATED APOPTOSIS - INDUGING LINGAND-RESISTAND MALIGNANT MELANOMAS BY QUERCETIN.
Department of Chemistry, Cleveland State University (GRHD) and Department of Molecular Cardioligy, Lerner Research Institute Cleveland Clinic Foundation, Cleveland. Ohaio, USA. - Received 8 August 2017 – Accepted 20 February 2018.
MEDICINE, Volume 95, Number %, February 2016 – Clinical Case Report – “Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a patient With Metastatic Bladder Cancer”.
Giuseppe Di Lorenzo – Antonio Verde.
The Oncologist- ELSEVIER, 2010; 15:200-211 – www.The Oncologist.comRandomized Phase III Clinical Trial of Different Arms of Treatment in 332 Patients with Cancer Cachexia – G. Mantovani – A. Maccio’- C. Madeddu – R. Serpe, E. Massa – M. Dessì – F. Panzone – P. Contu.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Issue: Environmental Stressors in Biology and Medicinee.
Ann. N.Y. Acad. Sci. ISSN 0077-8923 – 1259 (2012) 95 – 103 0 2012.
Dietary poliphenols in cancer prevention: the example of the flavonoid quercetin in leukemia.
C. Spagnulo, M Russo, S. Bilotto, Idolo Tedesco, B. Laratta and G.L. Russo.
British Jurnal of Cancer (2010).
Cancer Research UK – All rights reserved 0007 – 0920/10.
Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.
M. Russo, C. Spagnuolo, S. Volpe, A. Mupo, I. Tedesco and G.L. Russo.
Royal Society of Chemistry 2014. Reivew . Food & Function – Cite this: Food Function, 2014, 5 2393.
Istituto Scienze dell’Alimentazione, Consiglio Nazionale delle Ricerche, CNR, via Roma,64 – 83100, Avellino, Italy – E-mail: glrusso@isa.cnr.it –
The pleiotropic flavonoid Quercetin: from its metabolism to the inibition of protein kinases in chronic lynphocity leukemia.
G.L.Russo, M. Russo and C. Spagnuolo.
PERGAMON – Leukemia Research 27 (2003) 517-527.
Flavonoid Effects on normal and Leukemie cells.
Jane L. Liesveld, C. Abbound, Chaohui Lu, Cortis Mc Nair II, A. Menon, A. Smith, K. Rossel, A. P. Rapoport.
Department of Medicine, James P. Wilmot Cancer Center, The University of Rochester Medical Center, NY, USA – Creenebaunm Cancer Center, The University of Mariland, Baltimore, MD, USA.
REVIEW – America Society for Nutricion. Adv. Nutr.3: 39-46, 2012.
Therapeutic Potential of Quercetin to Decrease Blood Pressure: Review of Efficacy and Mechanisms.
Abigail J. Larson, J. David Symons and Thunder Jalili.
Departiment of Nutricion, Exercise, and Health Science, Central Washington University, Ellesburg, WA; Division of Nutricion, Universitry of UTAH, Salt Lake City, UT.
Europian Jurnal of Clinical Nutricion (2000) 54, 415-417.
Quercetin intake and the incidence of cerebrovascular disease.
P. Knekt, S Isotupa, H. Rissanen, M. Heliovaara, R. Jarvinen, S. Hakkinen, A. Aeomaa and A. Reunanen.
(NPHI) Helsinki Finland; Department Clinical Nutrition, Univrsity of Kuopio, Kuopio, Finland ; and Department of Phisiology, University of Kuopio, Kuopio Finland.
Transplantation – Vol. 66, 147-152, N° 2, July 27, 1998.
Effect of Bioflavonoids Quercetin and Curcumin on Ischemic Renal Injury.
A New Class of Renoproctetive Agents.
Danil A. Shoskes.
Division of Urology, Department of Surgery, Harbor-UCLA Medical Center, UCLA School of Medicine – Torrance, California 90509.
British Journal of Cancer (1996) 74, 172 – 177.
Drag resistance Gencitabine and Topotecan mediated by constitutive hsp 70 overexpression in vitro: implication of Quercetin as sensitiser in chemotherapy.
G. Sliutz, J. Kalseder, C. Tempfer, L. Orel, G. Holzer and MM Simon.
OGNI RIFERIMENTO SCIENTIFICO RIPORTATO NON COSTITUISCE SOSTITUZIONE DI TERAPIE IN ATTO DA PARTE DEL PAZIENTE E SI CONSIGLIA DI CONSULTARE IL PROPRIO MEDICO.